{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:49:17Z","timestamp":1791485357443,"version":"4.3.4"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX biosimilar CT\u2010P13 in IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single\u2010center observational study, we investigated all pediatric patients with IBD on maintenance IFX therapy who were switched from originator (Remicade\u00ae) to CT\u2010P13 (Inflectra\u00ae, switch A in cohort A) in 2018 and to CT\u2010P13 (Remsima\u00ae, switch B in cohort B) in 2022. Cohort C includes patients who underwent both switches. Demographics, disease activity, remission rates and IFX trough levels were collected from 6 months before to 6 months after each switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 42 children (cohort A) and 44 children (cohort B) had a single switch to CT\u2010P13; 14 (cohort C) had multiple switches. Median IFX trough concentration was 5.7 ([3.8\u20139.3) and 9.0 (6.2\u201311.7)\u2009\u00b5g\/mL versus 6.5 (3.9\u20138.6) and 9.22 (7.9\u201310.5)\u2009\u00b5g\/mL 6 months after switch in cohort A and B and 4.3 (3.4\u201310.9) versus 7.9 (6.9\u20139.7) and 9.3 (8.3\u201310.3) versus 9.4 (7.9\u201310.6) for respectively both switches in cohort C (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Antibodies to IFX developed in one patient post\u2010switch. Clinical\/biological remission rates remained stable. No clinically significant changes in inflammatory biomarkers and safety profile were noted before and after switch.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to CT\u2010P13 biosimilars appears to maintain remission without relevant changes in pharmacokinetics, disease activity, or adverse events in pediatric patients with IBD. Further studies are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70483","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:37:02Z","timestamp":1781260622000},"page":"447-455","source":"Crossref","is-referenced-by-count":1,"title":["Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease"],"prefix":"10.1002","volume":"83","author":[{"given":"Sofie","family":"De Groote","sequence":"first","affiliation":[{"name":"Department of Pediatric University Hospitals Leuven, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"van Hoeve","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology &amp; Hepatology &amp; Nutrition University Hospitals Leuven, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy Unit Department of Pharmaceutical and Pharmacological Sciences Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4117","authenticated-orcid":false,"given":"Ilse","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology &amp; Hepatology &amp; Nutrition University Hospitals Leuven, KU Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-320022"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002035"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12153"},{"key":"e_1_2_7_6_1","first-page":"57","article-title":"Biosimilars in pediatric IBD: updated considerations for disease management","volume":"16","author":"Dipasquale V","year":"2022","journal-title":"Biologics"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-2803.24612024-046"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003462"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2378090"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_2_7_11_1","unstructured":"European Medicines Agency Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU EMA\/627319\/20222;2022."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab099"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12357"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa036"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16312"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13131"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.036"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241301887"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab022"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0838"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16497"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000601"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000256"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jpr3.12134"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv233"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-024-00873-4"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002091"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx047"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15026"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003683"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1284181"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003890"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002141"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy111"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21493"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000239"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000709"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000434"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.143"},{"key":"e_1_2_7_41_1","unstructured":"RoelantsM HauspieR HoppenbrouwersK. Growth Charts Flanders 2004. Laboratorium voor Antropogenetica Vrije Universiteit Brussel Belgium. Accessed October 11 2023.http:\/\/www.vub.ac.be\/groeicurven\/english.html"},{"key":"e_1_2_7_42_1","unstructured":"U.D. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Institute NC.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1991.tb10268.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.029"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002408"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf335"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70483","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70483","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:12:52Z","timestamp":1788433972000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/jpn3.70483"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70483","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}